December 21, 2017 / 10:52 AM / in 8 months

BUZZ-Aeterna Zentaris: FDA approves growth hormone deficiency test

** Canadian drug developer’s U.S.-listed shares soar 87 pct to $3.76 premarket; biggest pct gainer among Nasdaq-listed stocks

** Over 12k shares changed hands, stock 4th most actively traded among all U.S. shares premarket

** Says U.S. FDA approves oral test, Macrilen, to diagnose adult growth hormone deficiency

** Macrilen stimulates secretion of growth hormone, which is then measured via blood samples

** Intends to launch Macrilen during Q1 2018

** Stock down 44.2 pct YTD (Reporting by Amy Caren Daniel in Bengaluru)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below